LGND - Ligand Pharmaceuticals Non-GAAP EPS of $1.80 beats by $0.43 revenue of $72.5M beats by $7.41M

Ligand Pharmaceuticals press release (NASDAQ:LGND): Q4 Non-GAAP EPS of $1.80 beats by $0.43. Revenue of $72.5M (+3.6% Y/Y) beats by $7.41M. As of December 31, 2021, Ligand had cash, cash equivalents and short-term investments of $341.1 million. 2022 Financial Guidance: Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million. These revenue components result in total revenue of $147 million to $172 million for the combined Ligand business vs. consensus of $185.06M.

For further details see:

Ligand Pharmaceuticals Non-GAAP EPS of $1.80 beats by $0.43, revenue of $72.5M beats by $7.41M